Sheikhpour Mojgan, Sadeghizadeh Majid, Yazdian Fatemeh, Mansoori Ali, Asadi Hassan, Movafagh Abolfazl, Shahraeini Seyed Sadegh
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
Iran Biomed J. 2020 Jan;24(1):24-9. doi: 10.29252/ibj.24.1.24. Epub 2019 Aug 28.
In recent years, nanotechnology with modern advances in the macromolecular design of nano-carriers has proved to be helpful in the development of drugs delivery systems. This research represents a novel co-administration of nano-vehicles, known as liposomes. Liposomes efficiently encapsulate curcumin and bromocriptine (BR) in a polymer structure, which results in enhanced aqueous solubility of the mentioned hydrophobic agents and higher bioavailability of the drugs.
Preparation of curcumin and BR liposomes were carried out by the thin film method, and the amounts of purified drug and its release were analyzed. After dose determination, the human lung cancer cells (QU-DB) were exposed to BR and curcumin liposomes for 12, 24, and 48 h. Then the viability and apoptosis assays were carried out by using tetrazolium dye and flow cytometry technique, respectively.
In this research, in vitro anti-cancer effects of former nano-formulations on lung cancer cells was confirmed, and no cytotoxicity effects of these nano-preparations were observed in the normal cells (HFLF-PI5).
Our findings suggest the nano-liposomal drugs as effective anti-cancer agents; however, additional clinical examinations are required.
近年来，随着纳米载体大分子设计的现代进展，纳米技术已被证明有助于药物递送系统的开发。本研究提出了一种新型的纳米载体联合给药方式，即脂质体。脂质体能够有效地将姜黄素和溴隐亭（BR）包裹在聚合物结构中，这使得上述疏水性药物的水溶性增强，药物的生物利用度更高。
采用薄膜法制备姜黄素和BR脂质体，并分析纯化药物的含量及其释放情况。确定剂量后，将人肺癌细胞（QU-DB）分别暴露于BR和姜黄素脂质体中12、24和48小时。然后分别使用四唑盐染料和流式细胞术进行细胞活力和凋亡检测。
本研究证实了先前纳米制剂对肺癌细胞的体外抗癌作用，并且在正常细胞（HFLF-PI5）中未观察到这些纳米制剂的细胞毒性作用。
我们的研究结果表明纳米脂质体药物是有效的抗癌药物；然而，还需要进行更多的临床检查。
